Canadian universities are making a bold move to keep the economic benefits of their groundbreaking research within the country. The University of Toronto (U of T) and McMaster University are leading the charge by anchoring a new $40-million venture capital fund focused on life sciences startups, primarily spinouts from their own institutions. This initiative is a significant step towards addressing a long-standing issue: Canadian researchers have often seen their discoveries commercialized abroad, leading to a lack of financial returns for the country. The fund, managed by Genesys Capital, is a strategic move to change this trend and foster a more robust domestic life sciences sector.
The $40-million fund is a joint effort between U of T, McMaster, and the Ontario government, with contributions from the Temerty Foundation and Royal Bank of Canada. U of T is investing up to $8 million, while McMaster is putting in $5 million. The Ontario government is providing up to $10 million through its Venture Ontario program. The fund will support companies working on medical devices and drugs for cancer, heart, and brain ailments, leveraging the expertise and innovations from both universities.
This is a significant shift for U of T and McMaster, as it marks the first time they have backed a venture capital fund. Both institutions have historically supported their spinouts through incubators and modest in-house funding, but this new fund represents a more substantial commitment to fostering entrepreneurship and commercializing research. The universities are using revenues from their technology transfer offices, which license patents for commercial use, to fund their stakes in the venture capital fund.
The initiative is part of a broader trend in Canadian universities to support their academics in becoming entrepreneurs. The Weston Family’s Wittington Innovation Fund, the Terry Fox Foundation and Canadian Cancer Agency’s joint venture with Lumira Ventures, and the University of Calgary’s seed funds are all examples of this growing trend. The goal is to create a more self-sufficient and impactful domestic life sciences sector, one that can benefit from the groundbreaking discoveries made by Canadian researchers.
The Genesys fund is particularly interesting because it is the first time U of T and McMaster have backed a venture capital fund. Both institutions have a strong track record of supporting spinouts, but this new fund represents a more significant and strategic commitment to fostering entrepreneurship and commercializing research. The universities are using revenues from their technology transfer offices to fund their stakes in the venture capital fund, which is a smart move that leverages existing resources to create a more robust domestic life sciences sector.
The fund is also significant because it is inspired by similar efforts from institutions like the Massachusetts Institute of Technology and the University of California, Berkeley. This indicates that Canadian universities are looking to the success of their international counterparts and are taking steps to emulate their strategies. The Genesys fund represents a big signal from the universities and the Ontario government of the importance of the life sciences sector and its long-term potential for the economy.
In my opinion, this is a crucial step towards building a more self-sufficient and impactful domestic life sciences sector. Canadian universities have a rich history of groundbreaking discoveries, but they have often struggled to commercialize them effectively. This new fund represents a significant commitment to changing that trend and fostering a more robust domestic life sciences sector. It is a smart move that leverages existing resources and expertise to create a more sustainable and impactful future for Canadian research and innovation.
